Industry 01 / 08 · Pharmaceuticals & Life Sciences
Positions Taken Before the Plant Earns
Machinery, raw materials and approvals are all settled long before the first batch is sold. Those positions set the economics for years.
Where the Pressure Sits
-
01
Capital machinery arrives before the plant earns
Classification and import structuring decide what the line actually costs to install. The decision is made once, under commissioning pressure, and is expensive to revisit afterwards.
-
02
Incentive eligibility is argued, not assumed
Industrial incentives and SRO benefits turn on how an investment is described and documented. The same plant qualifies or does not, depending on the position taken and the evidence behind it.
-
03
Raw-material classification repeats on every consignment
Active ingredient and excipient treatment is not a one-off ruling. A weak position compounds shipment after shipment rather than costing once.
Capabilities That Apply Here
The advisory areas this sector leans on most, each opening onto a full capability page.
Our Perspective
In pharmaceutical investment the fiscal position is set at import, not at sale. We work on the decisions that are hardest to reverse.
Related Work & Reading
Related Client Impact
Related Insights
Discuss a Business Challenge
Speak with our advisory team about the business issue behind the regulation.
Discuss a Business Challenge
Regulatory Insight.Commercial Intelligence.Practical Execution.
Practice areas
- Customs
- VAT
- Tax
- Trade
- Regulatory Strategy
- Commercial Advisory